Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 20;16(3):97.
doi: 10.3390/md16030097.

Function-Oriented Synthesis of Marine Phidianidine Derivatives as Potential PTP1B Inhibitors with Specific Selectivity

Affiliations

Function-Oriented Synthesis of Marine Phidianidine Derivatives as Potential PTP1B Inhibitors with Specific Selectivity

Jin Liu et al. Mar Drugs. .

Abstract

Phidianidines A and B are two novel marine indole alkaloids bearing an uncommon 1,2,4-oxadiazole ring and exhibiting various biological activities. Our previous research showed that the synthesized phidianidine analogs had the potential to inhibit the activity of protein tyrosine phosphatase 1B (PTP1B), a validated target for Type II diabetes, which indicates that these analogs are worth further structural modification. Therefore, in this paper, a series of phidianidine derivatives were designed and rapidly synthesized with a function-oriented synthesis (FOS) strategy. Their inhibitory effects on PTP1B and T-cell protein tyrosine phosphatase (TCPTP) were evaluated, and several compounds displayed significant inhibitory potency and specific selectivity over PTP1B. The structure-activity relationship (SAR) and molecular docking analyses are also described.

Keywords: Function Oriented Synthesis; PTP1B inhibitor; docking analysis; marine natural products; phidianidine; specific selectivity; structure-activity relationship.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structures of phidianidines (1 and 2) and their protein tyrosine phosphatase 1B (PTP1B) inhibitory analog 3.
Scheme 1
Scheme 1
Reagent and conditions: (a) NH2OH·HCl, NaOH, 50% EtOH, r.t., overnight; (b) Dichloro(p-cymene)ruthenium(II) dimer, CH3CN, 80 °C, 4 h; (c) NH2OH·HCl, NaHCO3, EtOH, r.t., 4 h; (d) HATU, DIPEA, CH2Cl2, r.t., 2 h; (e) NaOAc, 30% EtOH, reflux, overnight.
Scheme 2
Scheme 2
Reagent and conditions: (a) NH2OH·HCl, NaHCO3, EtOH, 65 °C, 4 h; (b) for 14a14k, and 14p14u: i, carboxylic acid, HATU, DIPEA, CH2Cl2, r.t., 2 h; ii, NaOAc, 30% EtOH, reflux, overnight. (c) For 14l14o, acyl chloride, K2CO3, toluene, reflux, 4 h.
Figure 2
Figure 2
Docking results for compounds 14c, 14p, and 14l14n on PTP1B, respectively (upper row: without showing surface of PTP1B, lower row: showing surface of PTP1B).

Similar articles

Cited by

References

    1. Tobin J.F., Tam S. Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes. Curr. Opin. Drug Discov. Dev. 2002;5:500–512. - PubMed
    1. Liu G., Trevillyan J.M. Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes. Curr. Opin. Investig. Drugs. 2002;3:1608–1616. - PubMed
    1. Johnson T.O., Ermolieff J., Jirousek M.R. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat. Rev. Drug Discov. 2002;1:696–709. doi: 10.1038/nrd895. - DOI - PubMed
    1. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.C., et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999;283:1544–1548. doi: 10.1126/science.283.5407.1544. - DOI - PubMed
    1. Klaman L.D., Boss O., Peroni O.D., Kim J.K., Martino J.L., Zabolotny J.M., Moghal N., Lubkin M., Kim Y.B., Sharpe A.H., et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 2000;20:5479–5489. doi: 10.1128/MCB.20.15.5479-5489.2000. - DOI - PMC - PubMed

MeSH terms